- Direction
- Unknown
- Own history
- —
- Peers
- 85th
- Persistence
- TRANSIENT
· Pharmaceutical Preparations
RESEARCH SNAPSHOTARS Pharmaceuticals, Inc.'s latest supported as-filed period reports revenue of $33.7M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 287.23% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -181.02% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 114.15% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 91.31% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -182.62% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 84.2%; Operating cash flow decreased 53.9%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 114.2%; Operating margin moved 12033 bp higher; Operating income decreased 29.1%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 114.2%; Operating margin moved 12033 bp higher; Operating income decreased 29.1%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 0.6%; SBC / revenue moved 265 bp higher.
2 evidence-backed componentsCash & equivalents changed -84.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
SPRY · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0002135296-26-000009SEC ↗4Sep 2, 2026Period Sep 1, 20260002149973-26-000004SEC ↗10-QAug 13, 2026Period Jun 30, 20260001193125-26-349140SEC ↗8-KAug 13, 2026Period Aug 13, 20260001193125-26-349127SEC ↗8-KJul 17, 2026Period Jul 15, 20260001193125-26-307773SEC ↗8-KJul 7, 2026Period Jul 6, 20260001193125-26-297554SEC ↗4Jul 2, 2026Period Jul 1, 20260002135296-26-000007SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 1, 2026Filed Oct 5, 2026 | Casale DonnPresident and CEO | Grant Or AwardDirect | 1,036,923 | $0 | $0 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 2, 2026 | Smith Margaret EkinsChief Commercial Officer | Grant Or AwardDirect | 1,001,738 | $0 | $0 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 2, 2026 | Casale DonnPresident | Grant Or AwardDirect | 898,456 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 13.96% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 36.83% · OPTIONAL
Working capital changed -36.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed -53.7% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Operating cash flow changed -53.9% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Operating income changed -29.1% from the comparable as-filed period.
Net income changed -38.9% from the comparable as-filed period.
Operating margin changed +12033 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001231919-26-000704